An R&D-led specialty chemicals company whose business is still primarily a pharma-intermediates engine, with smaller but strategic specialty-chemicals optionality in batteries and semiconductors. Getting the four validated CDMO products into revenue is the bet; they land from H2 FY27 and ramp mainly in FY28, while the price already banks about 44% growth.